Biotech Breakthroughs, Trans Snack Surges & a Spider Silk Revolution Power Small-Cap Rally

October 21, 2025

DENVER, Colo., Oct 21, 2025 (247marketnews.com)- Wall Street’s midday tone is risk-on, with biotech, food tech, and sustainable materials stocks seeing outsized moves.

iBio (NASDAQ:IBIO) is catching investor attention after announcing dual upcoming oral presentations on its lead candidate IBIO-610, a first-in-class Activin E antibody targeting obesity.

Preclinical data will be presented at ObesityWeek 2025 by Dr. Cory Schwartz, with follow-up remarks from CEO Dr. Martin Brenner at PEGS Europe 2025. “These findings add to a growing body of research that inhibiting Activin E signaling could deliver fat-selective weight loss… and enhance the benefits of GLP-1 therapies,” said Brenner.

With GLP-1s like Ozempic dominating the weight-loss conversation, iBio’s AI-enabled antibody discovery platform positions it as a next-gen contender or complement in a red-hot therapeutic space.

Kraig Biocraft Laboratories (OTCQB:KBLB) is spinning excitement in the biofabrication sector, launching its sixth spider silk production cycle of the year. The BAM-1 Alpha platform, a next-gen recombinant strain, is being hailed as a “major leap forward” in sustainable fiber production.

CEO Kim Thompson called the development “exhilarating,” emphasizing years of behind-the-scenes innovation now poised for commercial scalability without added infrastructure costs.

Beyond Meat (NASDAQ:BYND) popped after announcing the launch of its Beyond Burger 6-Pack in over 2,000 Walmart (NYSE:WMT) stores nationwide. As food inflation bites into household budgets, Beyond’s new value pack delivers 21g protein, zero cholesterol, and low saturated fat at a lower price point.

CEO Ethan Brown said the expansion supports the company’s mission to make plant-based protein more accessible to cost-conscious consumers.

Minerva Neurosciences (NASDAQ:NERV) surged after announcing a $200 million private placement to fund a Phase 3 confirmatory trial and a possible NDA resubmission for roluperidone, a treatment for negative symptoms of schizophrenia—a condition with no approved therapies.

Backers include Vivo Capital, Janus Henderson, and Foresite Capital, with $80 million upfront and the remaining $120 million in milestone-based warrants. CEO Dr. Remy Luthringer described the funding as “transformational,” signaling a bold second act for the embattled biotech.

VSee Health (NASDAQ:VSEE) rocketed higher after revealing a multi-year, $10 million+ teleradiology deal, doubling its annual recurring revenue and expanding its hospital reach across the U.S.

The contract, live since June, could bring $5M+ in upside potential. Co-CEO Dr. Imo Aisiku called the win a “game-changer,” underscoring VSee’s positioning in the telehealth revolution.

BranchOut Food (NASDAQ:BOF) rallied after reporting its strongest quarter ever, driven by record production, soaring revenues, and a 92% reduction in notes payable.

Highlights:

  • Q3 revenue hit ~$3.2M, YTD revenue up 93% to $9.7M.
  • 38,500 kg of product output in September, hitting breakeven scale.
  • $16M annualized run rate reached for the first time.
  • Successful ATM equity program completed.
  • New strawberry product cracked the top 10 in club sales nationally.
  • Committed to purchasing a new EnWave REV™ 120kW machine to expand capacity in 2026.

CEO Eric Healy called it a “transformative quarter,” noting that with most R&D costs behind, the company is set for stronger margins and profitability in 2026.

Danaher Corporation (NYSE:DHR) posted solid Q3 results:

  • Revenue grew 4.5% YoY to $6.1B.
  • EPS of $1.89 (non-GAAP) beat expectations.
  • Free cash flow of $1.4B reflects strong execution.

CEO Rainer Blair praised bioprocessing momentum and resurgent respiratory revenue at Cepheid, while reaffirming full-year EPS guidance of $7.70–$7.80.

Rani Therapeutics (NASDAQ:RANI) jumped following a potential $1.085 billion collaboration with Chugai Pharmaceutical Co., focused on integrating Rani’s oral delivery RaniPill™ technology with Chugai’s biologics for rare diseases and immunology.

Rani will receive:

  • $10M upfront
  • Up to $75M in development milestones
  • $100M in commercial sales milestones
  • Royalties on future sales

Rani also closed a $60.3M private placement, led by Samsara BioCapital and other top-tier investors, to further fund development.

CEO Talat Imran called it a “breakthrough” for biologics, offering hope for needle-free treatments in high-need areas.

For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com

Please click here to read the full Kraig Labs analyst report on 247marketnews.com.

Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated by one or more featured companies for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. Please go to https://247marketnews.com/kblb-disclosure/ for further KBLB and 247marketnews.com disclosure information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (KBLB, BOF, BYND, WMT, RANI, DHR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.